EBNA3A and EBNA3C help establish a long-term latency and subsequent lymphoma development by blocking B-cell differentiation to plasma cell phenotype through transcriptional activation of the cyclin-dependent kinase inhibitor p18INK4c and the master transcriptional regulator of plasma cell differentiation, B lymphocyte-induced maturation protein-1 (BLIMP-1) [81]. The gene discussed is PRDM1; the disease is lymphoma.